Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 3/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 3/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913482 | 0.87 | RAB9A (0.46) | ITGA4ITGB7RAB9APDE1CCYP19A1 | |
| SCHEMBL10093003 | 0.81 | NR1D1 (0.45) | ITGA4ITGB7NR1D1MAPT | |
| SCHEMBL2060836 | 0.79 | NR1D1 (0.45) | ITGA4ITGB7NR1D1MAPTKMT2A | |
| SCHEMBL27780713 | 0.78 | RAB9A (0.39) | ITGA4ITGB7RAB9APDE1CCYP19A1 | |
| SCHEMBL782973 | 0.77 | ALDH1A1 (0.47) | MAPTKMT2A | |
| SCHEMBL12330698 | 0.75 | ALDH1A1 (0.42) | ITGA4ITGB7RAB9ANR1D1 | |
| SCHEMBL13721704 | 0.74 | HDAC3 (0.47) | — | |
| SCHEMBL12722685 | 0.74 | CTSL (0.44) | KMT2A | |
| SCHEMBL782974 | 0.74 | ALDH1A1 (0.44) | MAPTKMT2A | |
| SCHEMBL6046660 | 0.73 | NR1D1 (0.51) | RAB9ANR1D1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | ITGA4 1883/4885ITGB7 3481/4885RAB9A 2927/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | ITGA4 1883/4885ITGB7 3481/4885RAB9A 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.